Send Inquiry

Request To Call Back

ERLONAT 150 MG ERLOTINIB TABLETS

Get a Price/Quote

ERLONAT 150 MG ERLOTINIB TABLETS Specification

Origin of Medicine
India

Indication
Treatment of locally advanced or metastatic non-small cell lung cancer, pancreatic cancer

Pacakaging (Quantity Per Box)
30 Tablets per box

Dosage Form
Oral

Salt Composition
Erlotinib Hydrochloride 150 mg

Drug Type
Allopathic

Ingredients
Erlotinib Hydrochloride

Physical Form
Tablets

Function
Antineoplastic agent, EGFR tyrosine kinase inhibitor

Recommended For
Patients with non-small cell lung cancer and pancreatic cancer

Dosage
As directed by physician, typically 150 mg once daily

Dosage Guidelines
Take on an empty stomach (at least 1 hour before or 2 hours after food)

Suitable For
Adults

Quantity
30 Tablets

Storage Instructions
Store below 30C, protected from moisture and light

Marketed By
NATCO Pharma Ltd.

Colour
White to off-white

Caution
Not recommended during pregnancy or breastfeeding; consult your doctor

Prescription/Non Prescription
Prescription

HSN Code
30049099

Route of Administration
Oral

Trade Name
ERLONAT

Strength
150 mg

Approval
Approved by CDSCO, India

Shape
Round

Usage
For hospital and pharmacy use only

Side Effects
Common side effects include rash, diarrhoea, loss of appetite, and fatigue

Shelf Life
2 years from date of manufacture

Therapeutic Class
Anticancer

ERLONAT 150 MG ERLOTINIB TABLETS Trade Information

Packaging Details
PACK OF 30 TABLETS

Main Domestic Market
All India

About ERLONAT 150 MG ERLOTINIB TABLETS

Erlonat 150 Mg Tablets

Specification

Product Name - Erlonat 150 Mg Tablets
Content - Erlotinib Hydrochloride
Form - Tablets
Strength - 25 Mg, 100Mg, 150 Mg
Packing - Pack Of 30 Tablets
Manufactured By : Natco

Note :-ErlonatIs A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug..............

Dosage & Administration

ERLONAT 150 mg should be taken orally on an empty stomachat least one hour before or two hours after eating. This routine maximizes absorption and therapeutic benefit. Dosage is determined by your healthcare provider, and its usually 150 mg once daily. Always follow physician instructions strictly to ensure safety and effectiveness.

Indications & Therapeutic Uses

ERLONAT is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer and pancreatic cancer in adults. Its active ingredient, Erlotinib Hydrochloride, helps inhibit the growth of cancer cells by targeting the epidermal growth factor receptor (EGFR), making it an essential part of anti-cancer therapy under medical guidance.

Storage & Shelf Life

To maintain efficacy, store ERLONAT tablets below 30C, protected from moisture and light. The shelf life is two years from the date of manufacture. Always keep the medication in its original packaging and out of reach of children, ensuring it remains safe and effective for its intended use.

FAQs of ERLONAT 150 MG ERLOTINIB TABLETS:

Q: How should ERLONAT 150 mg Erlotinib Tablets be taken for best results?

A: ERLONAT Tablets should be taken orally on an empty stomach, at least one hour before or two hours after food, as directed by your physician. This helps maximize drug absorption and therapeutic effect.

Q: What conditions are treated with ERLONAT 150 mg Erlotinib Tablets?

A: ERLONAT is prescribed for adults with locally advanced or metastatic non-small cell lung cancer and pancreatic cancer, serving as an effective EGFR tyrosine kinase inhibitor.

Q: When should I consult my doctor before starting ERLONAT 150 mg?

A: You should always consult your doctor prior to using ERLONAT, especially if you are pregnant, breastfeeding, or have pre-existing health conditions. It is not recommended during pregnancy or breastfeeding.

Q: Where should ERLONAT 150 mg Tablets be stored to maintain their quality?

A: Store the tablets below 30C, away from moisture and light, in the original packaging, to preserve their potency throughout their shelf life of two years from the date of manufacture.

Q: What is the process for obtaining ERLONAT 150 mg Tablets?

A: ERLONAT is a prescription medicine approved by CDSCO, India, and is available through authorized hospitals, pharmacies, and certified distributors. A licensed medical professional must prescribe it.

Q: Are there any side effects associated with ERLONAT 150 mg Erlotinib Tablets?

A: Common side effects include rash, diarrhoea, loss of appetite, and fatigue. Report persistent or severe symptoms to your doctor for appropriate management and support.

Q: What benefit does ERLONAT 150 mg offer for cancer patients?

A: ERLONAT provides targeted antineoplastic action, inhibiting cancer cell growth in non-small cell lung cancer and pancreatic cancer, helping improve treatment outcomes under medical supervision.

Tell us about your requirement